Roche’s an­ti-TIG­IT drug shows ze­ro re­sponse as monother­a­py — but da­ta back ef­fect for lung can­cer sub­set

Roche has post­ed some new, ear­ly-stage da­ta on its an­ti-TIG­IT drug tiragolum­ab in sol­id tu­mors that are be­ing stud­ied for fresh signs on the close­ly-watched class. And an­a­lysts won­der whether an ab­sence of any ef­fect as a monother­a­py — not good — will be out­weighed by added da­ta that their com­bo with their PD-L1 Tecen­triq works in a sub­set of lung can­cer pa­tients.

Among the 24 pa­tients signed up for the Phase Ia study us­ing es­ca­lat­ing dos­es of tiragolum­ab, none demon­strat­ed an ob­jec­tive re­sponse to the monother­a­py, ac­cord­ing to the ab­stract post­ed by AACR.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.